Oncoforum Urology: Prostate Cancer 2008 at a Glance Nicolas Mottet  European Urology Supplements  Volume 8, Issue 12, Pages 843-847 (December 2009) DOI: 10.1016/j.eursup.2009.09.005 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 The risk of nodal disease in men with ≥50% or <50% of the biopsy cores being positive for prostate cancer [4]. European Urology Supplements 2009 8, 843-847DOI: (10.1016/j.eursup.2009.09.005) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Use of prostate-specific antigen (PSA) progression to predict overall survival in patients with metastatic prostate cancer treated with continuous androgen deprivation therapy (phase 3 S9346 trial) and docetaxel or mitoxantrone plus prednisone (phase 3 S9916 trial) [5]. European Urology Supplements 2009 8, 843-847DOI: (10.1016/j.eursup.2009.09.005) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 3 Benefit of adjuvant radiotherapy to radical prostatectomy among men with pT3 prostate cancer enrolled in the Southwest Oncology Group (SWOG) 8794 trial [15]. European Urology Supplements 2009 8, 843-847DOI: (10.1016/j.eursup.2009.09.005) Copyright © 2009 European Association of Urology Terms and Conditions